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Selective inactivation of critical cysteine residues in human immunodeficiency virus type one (HIV-1) was observed after treatment with
4-vinylpyridine (4-VP), with and without the membrane-permeable metal chelator N,N,N′,N′-tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN).
Chromatographic analysis showed that cysteines contained within nucleocapsid zinc fingers, in the context of whole virus or purified protein, were
essentially unreactive, but became reactive when a chelator was included. Virus treated with 4-VP showed only a modest decrease in infectivity; after
TPEN addition, nearly complete inactivation of HIV-1 occurred. Similarly, quantitation of viral DNA products from 4-VP-treated virus infections
showed no significant effects on reverse transcription, but did show a 14-fold reduction in proviruses; when TPEN was added, a 105-fold decrease in
late reverse transcription products was observed and no proviruses were detected. Since 4-VP effectiveness was greatly enhanced by TPEN, this
strongly suggests that modification of nucleocapsid zinc fingers is necessary and sufficient for HIV-1 inactivation by sulfhydryl reagents.
Published by Elsevier Inc.Keywords: HIV-1; Nucleocapsid; Zinc finger; Reverse transcription; Provirus; Sulfhydryl reagentsIntroduction
Nucleocapsid (NC) proteins perform several essential func-
tions in the human immunodeficiency virus type one (HIV-1)
replication cycle. As part of the Gag polyprotein, NC recognizes
and packages the viral genome during assembly of new virions
(Vogt, 1997). Once it is cleaved from Gag by the viral protease,
the small and highly basic NC protein acts as a nucleic acid
chaperone during reverse transcription (reviewed in Levin et al.,
2005; Rein et al., 1998) and integration (Buckman et al., 2003;
Carteau et al., 1997, 1999; Poljak et al., 2003; Thomas et al., 2006;
Thomas and Gorelick, in press), and also protects newly
synthesized viral DNA (vDNA) from cellular nucleases (Buck-
man et al., 2003; Tanchou et al., 1998; Thomas et al., 2006).⁎ Corresponding author. Fax: +1 301 846 7119.
E-mail address: gorelick@ncifcrf.gov (R.J. Gorelick).
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doi:10.1016/j.virol.2008.01.045NC is mostly unstructured when not bound to nucleic acids
(Lee et al., 1998), but two features are notable. Clusters of
basic residues and zinc finger motifs facilitate binding to
nucleic acids both nonspecifically and to specific, high affinity
sequences. The basic residues bind to the phosphodiester
backbone of nucleic acids, and the zinc fingers allow NC to
form highly specific interactions with nucleobases (De Guz-
man et al., 1998; Fisher et al., 1998, 2006). As the name
implies, Zn2+ is at the core of retroviral NC zinc finger
domains and forms a tetrahedral coordination complex (Bess
et al., 1992; Chance et al., 1992; Summers et al., 1992) with
cysteine and histidine residues in the characteristic, highly
conserved pattern -C-X2-C-X4-H-X4-C- (CCHC; Berg, 1986;
Covey, 1986; Henderson et al., 1981). Except for gammare-
troviruses, which have a single zinc finger, all orthoretro-
viruses have two copies of this motif.
Retroviral NC zinc fingers are small, only fourteen residues in
length, but crucial for viral replication. Zn2+ coordination is es-
sential for maintaining the correct structure of these domains, and
pointmutations that eliminate Zn2+ binding result in noninfectious
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Zn2+ binding, such as cysteine to histidine, histidine to cysteine, or
exchanging the positions of the zinc fingers can completely block
viral replication (Buckman et al., 2003; Gorelick et al., 1993,
1999; Guo et al., 2002; Tanchou et al., 1998). Additionally, the
two zinc fingers in HIV-1NC are not equivalent in either their role
in viral replication or their chemical reactivity. The N-terminal
zinc finger plays a more prominent role in replication (Gorelick
et al., 1993, 1999). Experimental modification of cysteine residues
in purifiedNC has provided evidence that the two zinc fingers also
differ in chemical reactivity, the C-terminal zinc finger, and es-
pecially Cys49, being more available for reaction with electro-
philes (Chertova et al., 1998; Hathout et al., 1996; Huang et al.,
1998a; Maynard et al., 1998; Tummino et al., 1996).
NC cysteine residues, critical for maintaining the structure of
the zinc finger domains, make attractive targets for chemical in-
activation of HIV-1. Electrophilic molecules with sufficient redox
potential (Topol et al., 2001) that are also capable of crossing the
viral membrane will oxidize NC cysteines, thereby destroying the
zinc finger structure and inactivating the virus (Rice et al., 1993,
1995). For example, 2,2′-dipyridyl disulfide (also known as
Aldrithiol-2; AT-2) is used to chemically inactivate HIV-1 for
experimental and vaccine research purposes in both animals
and humans (Lifson et al., 2004; Lu et al., 2004b; Rossio et al.,
1998). NC can similarly be modified by the sulfhydryl reagent
N-ethylmaleimide (NEM), which alkylates the cysteine res-
idues and consequently destroys the zinc finger structure of NC
(Chertova et al., 1998; Morcock et al., 2005).
While perturbing cysteines within NC zinc fingers is suf-
ficient for inactivating HIV-1, the necessity of modifying these
residues is unclear. Reagents such as AT-2 and NEM can react
with any viral protein that contains cysteine, not just NC, so the
possibility exists that modification of these other proteins may
contribute to the inactivation of HIV-1. A reagent that is un-
reactive with the Zn2+-bound cysteines of NC would be useful
for investigating both the importance of these residues and the
importance of other cysteine-containing proteins to the chemicalFig. 1. Inactivation of HIV-1. Error bars represent the standard deviation of between tw
were neutralized with 4 mM GSH and 100 µM Zn2+, respectively. (A) Virus was trea
determined from β-galactosidase expression of TZM-bl cells, as described in Material
(B) Effect of 4-VP on virus infectivity, with and without TPEN; virus inactivation w
1 mM 4-VP (□), and 1 mM 4-VP+50 µM TPEN (♦), and viral titers were determine
other treatments are significant based on ANOVA and post hoc Tukey tests, with pb0
were typically b1.6 blue cell forming units per mL (BCFU/mL).inactivation of HIV-1; we present evidence that the sulfhydryl
reagent 4-vinylpyridine (4-VP) possesses this characteristic.
We show in experimentswith purified proteins in vitro that 4-VP
was essentially unreactive with Zn2+-bound NC but reacted readily
with apo-NC. Intact HIV-1 particles were also treated with 4-VP,
alone or in the presence of a membrane-permeable divalent metal
ion chelator. The effects of these treatments on infectivity and early
steps in viral replication were examined in reporter cell and
quantitative PCR assays.
Alone, 4-VP reduced virus infectivity moderately (∼10-fold),
which could be correlated with a reduction in the number of
vDNA integrations into the host genome. This correlation indi-
cates that in addition to NC, free cysteine residues in other
proteins may be needed for maximum integration efficiency.
However, 4-VP in combination with a membrane-permeable
chelator rendered integration undetectable. In addition, the
synthesis of both early and late vDNA products was severely
inhibited and HIV-1 titer was significantly affected. These results
suggest that the cysteine residues of NC's zinc fingers are the
principal targets in sulfhydryl-mediated chemical inactivation of
HIV-1.
Results
Virus infectivity
We performed experiments to determine the effect of drug
treatment on virus infectivity. After treating HIV-1 with 4-VP or
4-VP+N,N,N′,N′-tetrakis(2-pyridylmethyl)-ethylenediamine
(TPEN; a membrane-permeable metal chelator), infectivity was
measured using a β-galactosidase reporter cell assay. A dose–
response experiment demonstrated that 4-VP treatment had a
rather modest effect on infectivity. After 24 h of treatment with
1 mM 4-VP, the highest concentration used, viral titer decreased
by only 1.1 orders of magnitude with respect to untreated virus
(Fig. 1A); lower concentrations had progressively less of an
effect.o and seven samples for each point. After treatment, unreacted 4-VP and TPEN
ted with various concentrations of 4-VP for 24 h, then the infectious titers were
s and methods. Titers are reported as blue cell forming units per mL (BCFU/mL).
as monitored over 24 h. HIV-1 was incubated with PBS (○), 50 µM TPEN (▲),
d as above. For times 2 h and later, the differences between VP+TPEN and the
.001. Medium only was used to determine background levels of blue cells, which
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viral proteins with sulfhydryl reagents in the context of intact
virions was tested by treating HIV-1 with the metal chelator
TPEN at 50 µM in combination with 1 mM 4-VP. TPEN has
several properties which make it well suited for this purpose. Its
affinity for Zn2+ (log K=15.6; Anderegg et al., 1977) is greater
than that of the HIV-1 NC zinc fingers (log K=14.54 and 13.23
for the N- and C-terminal zinc fingers, respectively; Mély et al.,
1996). Additionally, TPEN is membrane permeable and has low
affinity for calcium and magnesium ions at physiological pH
(Arslan et al., 1985). Samples of virus treated with the different
combinations of drugs and relevant controls were collected over
a 24 h period and assayed for infectivity as before (Fig. 1B). The
infectivity of untreated virus decreased by 0.3 orders of mag-
nitude over the 24 h period. Consistent with the dose–effect
results (Fig. 1A), 1 mM 4-VP reduced infectivity by 1.3 orders of
magnitude. TPEN alone reduced viral infectivity by 0.6 orders of
magnitude (not significantly different from untreated virus), sug-
gesting that viral proteins were able to reacquire Zn2+ removed
by the chelator. However, whenHIV-1was exposed to both 1mM
4-VP and 50 μM TPEN, viral infectivity was reduced by 4.5
orders of magnitude after 24 h (for time points 2 h and later, the
difference was significant compared to all other treatments;
pb0.001 based on ANOVA and post hoc Tukey tests; Fig. 1B).
Reagent control treatments of virus [4 mM reduced glutathione
(GSH; used to quench 4-VP), 100 μM Zn2+ (used to prevent
TPEN cytotoxicity), 4 mM GSH+100 μM Zn2+, or 0.05% (v/v)
ethanol (the solvent for TPEN)] did not cause any reduction in
titer compared to untreated virus (data not shown). Individually,
4-VP and TPENwere poorly virucidal, but when the two reagents
were used together, they effectively and significantly inactivated
HIV-1, which supported the idea that the majority of the critical
Cys residues are bound to Zn2+.Table 1
Viral DNA intermediates
Treatment RT
activity a
CCR5 copy #
(×104)
Relative copy num
R-U5 R
Untreated HIV-1 100±0.19 7.1±0.1 100±6 d 1
GSH 104±0.17 6.4±0.7 137±7 1
Zn2+ 111±0.15 5.0±0.09 117±7 1
Zn2++GSH 115±0.21 8.0±1 100±12 8
TPEN 87±0.21 6.8±0.5 70±9 4
4-VP 139±0.16 6.6±0.7 49±18 3
TPEN+4-VP 80±0.14 6.7±0.5 6.7±0.4 0
IND116N 46±0.21 9.0±2 39±2 2
Ethanol 102±0.16 6.5±0.7 90±9 6
Heat inactivated i 0 6.6±0.1 0.03±0.02 0
Negative control j 0 8.1±0.04 – –
a Exogenous template reverse transcriptase activity. 100%=(1.1±0.2)×106 count
b Reverse transcription efficiency was defined as the ratio of R-5′UTR/R-U5 cop
c Integration efficiency was defined as the ratio of provirus/R-5′UTR copy numb
d 100%=(8.3±0.4)×105 copies per sample. Copy numbers were corrected for DN
e 100%=(3.7±0.1)×105 copies per sample.
f 100%=(1.5±0.2)×105 copies per sample. The limit of detection for the proviru
g Actual efficiency was 0.45±0.02 (equivalent to R-5′UTR/ R-U5 copies).
h Actual efficiency was 0.40±0.05 (equivalent to provirus/ R-5′UTR copies).
i Virus was incubated at 68 °C for 20 min.
j Mock transfections of HEK 293T cells with sheared salmon sperm DNA.Reverse transcription
To determine how the 4-VP and 4-VP+TPEN treatments
reduced infectivity, we examined the activity of reverse transcrip-
tase (RT) from treated viruses, as well as reverse transcription in
cells after infectionwith treated viruses. RTactivity in viral lysates
was measured with an exogenous template assay for RNA-
dependentDNApolymerase activity (Gorelick et al., 1990, 1999).
Treating HIV-1 for 18 h at 37 °C with 1 mM 4-VP and 50 μM
TPEN, singly or combined, did not significantly reduce RT ac-
tivity (Table 1). Virus treated with 4 mM GSH, 100 μM Zn2+, or
0.05% (v/v) ethanol also retained similar levels of exogenous
template RT activity. Heat-inactivated virus had no detectable RT
activity, as expected. Because drug treatment did not significantly
reduce RT activity in the exogenous template assay, it is unlikely
to be the principal target in virio. Therefore, we investigated the
ability of treated viruses to reverse transcribe their genomes after
infection of cells.
HIV-1 pseudotyped with vesicular stomatitis virus G (VSV-G)
protein was treated for 18 h with 4-VP, with and without TPEN.
The reagents were neutralized with GSH or Zn2+, as relevant,
prior to application to cells. The treated virus preparations were
used to infect human osteosarcoma (HOS) cells for 24 h. Specific
vDNA products were quantitated using real-time PCR. The data
were normalized for recovered total DNA using CCR5 copy
numbers from the HOS cells (similar CCR5 levels among all of
the samples also verified the absence of cytotoxicity associated
with treatments; Table 1) and for input virus using RT activity, as
described previously (Buckman et al., 2003; Thomas et al., 2006).
Copy numbers relative to untreated virus are presented for minus-
strand strong-stop DNA (R-U5), plus-strand transfer DNA (R-5′
UTR), and provirus (Alu-LTR); all are reported as percentages of
untreated virus. In addition to the individual species detected, theber Relative efficiency
-5′UTR Provirus Reverse transcription b Integration c
00±4 e 100±18 f 100±7 g 100±18 h
15±17 87±15 84±13 76±17
11±5 92±16 95±7 83±15
2±3 78±10 82±10 95±12
8±7 26±8 68±13 55±19
1±8 7±1 63±28 22±6
.081±0.002 – 1.2±0.1 –
5±3 – 65±8 –
7±8 43±11 75±11 64±18
.012±0.001 – – –
– – –
s of TMP incorporated per minute. Samples were analyzed in triplicate.
y numbers and shown as a percentage of untreated HIV-1.
ers and shown as a percentage of untreated HIV-1.
A recovery and RT activity.
s assay is 100 copies (Thomas et al., 2006).
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sented as the percent efficiency of untreated virus was calculated
from the ratio of R-5′UTR to R-U5 copy numbers (indicates
conversion of early to late vDNA products). Similarly, integration
efficiency for a particular treatment, presented as the percent
efficiency of untreated virus, was calculated from the ratio of
provirus to R-5′UTR copy numbers (indicates conversion of late
vDNA products to proviruses; Table 1).
Treating viruses with the combination of 4-VP+TPEN re-
duced vDNA synthesis significantly more than 4-VP alone. AfterFig. 2. HPLC analysis of HIV-1 treated with 4-VP, with and without TPEN. Absorbanc
of 255 and 280 nm absorbance from the same sample, depicting the elution of NC and
VP+50 µM TPEN for 3 h, or (D) 4-VP+TPEN for 18 h. HIV-1 treated for 18 h with
normalized as described in Materials and methods.treatment with 4-VP, HIV-1 synthesized vDNA with a modest
(∼40%) decrease in reverse transcription efficiency, while the
efficiency of provirus formation was reduced ∼80% (Table 1).
Combining TPENwith 4-VP had a much greater effect on vDNA
synthesis. Reverse transcription efficiency was reduced 99% and
proviruses could not be detected, which is consistent with the loss
of infectious titer following treatment with 4-VP+TPEN
described above (Fig. 1B). Control virus treatments using Zn2+
andGSH synthesized vDNA in amounts similar to untreated virus
in the HOS cell infections. HIV-1 treated with TPEN or ethanole at 206 nm is shown in panels on the left. Panels on the right show enlargements
derivatives. Virus was (A) untreated, (B) treated with 1 mM 4-VP for 18 h, (C) 4-
TPEN alone was equivalent to untreated virus (data not shown). The data were
Fig. 3. HPLC analysis of purified HIV-1 NC p7 protein after 4-VP treatment.
Absorbance at 206 nm is shown on the left, 260 and 280 nm absorbance on the right.
(A) HIV-1 NC p7 in 10 mM Tris buffer, pH 7.5, was treated with 4-VP only
(~2000×[Cys]) for 195 min or (B) with 4-VP (~1000×[Cys])+EDTA for 20 min.
152 D.R. Morcock et al. / Virology 375 (2008) 148–158showed only a small decrease in vDNA levels. Synthesis of
vDNA by IND116N (an integration-negative mutant virus; Engel-
man et al., 1995) was reduced, in agreement with previous reports
(Buckman et al., 2003; Thomas et al., 2006). Heat-inactivated
HIV-1 showed negligible levels of vDNA signals, indicative of
very low levels of contaminating plasmid present in the samples
(b0.03% of the untreated samples). Despite the presence of active
RT, the combination of 4-VP and TPEN severely inhibited the
earliest steps of reverse transcription.
HPLC analysis
Although 4-VP inactivated HIV-1 to a limited extent, the
reagent did have an effect on infectivity and integration of vDNA,
indicating that proteins within the virus reacted with 4-VP; the
effect was much greater when a metal chelator was included. To
identify the principal viral proteinsmodified by 4-VP, HIV-1 from
clarified pNL4-3 transfection supernatant was treated as follows.
Virus was either untreated, treated for 18 h with 1 mM 4-VP only,
or for 3 h or 18 h with 1mM4-VP+50 μMTPEN. Virus was then
collected by ultracentrifugation, lysed and reduced, then analyzed
with reverse phase microcapillary high-pressure liquid chromato-
graphy (HPLC). Pyridylethylation could be identified by the
appearance of a new peak eluting earlier than the parent protein
peak and by an increase in the ratio of absorbance at 255–260 nm
relative to 280 nm (because of ethylpyridine adding to tryp-
tophan's absorbance). Viral proteins p1 (also known as spacer
peptide 2; SP2) and p6, which lack cysteine, were used as internal
standards for peak alignments. Fig. 2A shows the elution pattern
of Gag proteins from untreated virus, which had an NC A255/A280
ratio of 0.55; treatment with TPEN alone for 18 h was equivalent
to untreated virus (data not shown).
NCdid not react significantly inHIV-1 treatedwith 1mM4-VP
(NC A255/A280=0.62; Fig. 2B). A shoulder did appear on the NC
peak, but this may have been the result of 4-VP reacting with
spontaneously oxidized NC, since A255/A280 increased to 1.82.
Spontaneous oxidation of cysteine in the zinc finger domains of
NC to disulfide or other species is common in purified virus (L.
Henderson, unpublished observations). Such oxidation would
decrease Zn2+ coordination, thus leaving the remaining free
cysteines susceptible to 4-VP. Despite this, the bulk of NC was
unmodified by 4-VP as judged by 255 and 280 nmabsorbance and
the peak's elution position.
Likewise, neither MA nor CA in whole virus reacted ap-
preciably with 4-VP (with or without TPEN). Separate experi-
ments with purified proteins identified the elution positions of
4-VP-modified MA and CA, and confirmed that the 4-VP-
modified forms could be separated from the unmodified proteins
under our chromatographic conditions (data not shown). Both
proteins were recovered in their unmodified state from treated
virus in yields exceeding 85% of expected values. In addition,
the absence of a peak at the elution position for modified MA
indicates that this species is absent in the modified virus (Fig. 2).
The elution position formodifiedCA is complicated by unknown,
presumably cellular material, but the peak had low 255 nm ab-
sorbance indicating that it had not been pyridylethylated and
therefore is likely irrelevant (data not shown). Taken together,these observations strongly support the conclusion that neither
MA nor CA is modified by our treatments.
Combining TPEN with 4-VP dramatically increased the
derivatization of NC. After 18 h, NC from virus treated with 4-
VP alone had reacted fractionally as judged by its 255/280 nm
absorbance ratio and its elution position (Fig. 2B). In contrast,
after only 3 h of exposure to 1 mM 4-VP and 50 μM TPEN,
unmodified NC had been replaced by two new peaks (Fig. 2C),
corresponding to intermediate and final reaction products, whose
increased absorbance at 255 nm (A255/A280=2.46 and 3.51,
respectively) was characteristic of pyridylethylated protein. The
intermediate product was more abundant at 3 h, but after 18 h of
treatment the final product was predominant (Fig. 2D). In the
latter case, two intermediate peaks (A255/A280=1.9 and 2.6) were
observed in addition to the final product (A255/A280=3.4). Based
on the results reported byChertova et al., the intermediate product
likely was NC modified on the C-terminal zinc finger, and the
final product corresponded to protein modified on both zinc
fingers (Chertova et al., 1998). 4-VP reacted with NC in whole
virus only when Zn2+ was removed from the protein (e.g., via the
addition of TPEN), exposing its cysteine residues.
HPLC analysis of NC protein
To further elucidate the mechanism of NC modification, we
examined purified recombinant HIV-1NL4-3 NC (p7 form) treated
with 4-VP, with or without metal chelators. A solution of 7.7 μM
NC (with 6 cysteines), 89 mM 4-VP, and 10 mM Tris buffer, pH
7.5, in a total volume of 20 μL was reacted at 25 °C for 195 min.
and then injected onto an HPLC column. Despite the∼2000-fold
excess of 4-VP over cysteine, no derivatized NC was detected
(Fig. 3A); however, as with whole virus, a shoulder with increased
A260 relative to A280 appeared, which may again stem from
spontaneous oxidation of NC exposing cysteine during the reac-
tion (see above). Next, a solution of 6.3 μM NC, 35 mM 4-VP,
5 mM EDTA (for removal of Zn2+), and 10 mM Tris buffer, pH
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injected onto anHPLCcolumn. In the absence of coordinatedZn2+,
NC reacted extensively and rapidly with 4-VP, eluting earlier from
the HPLC column with increased absorbance at 260 nm relative to
280 nm (Fig. 3B). Unmodified NC was not observed after this
treatment.
Separately, NC dissolved in HPLC lysis buffer plus 10 mM
EDTAwas treated with excess 4-VP to produce fully derivatized
NC for comparison with treated virus. Protein purified by HPLC
was collected for mass spectrometry. The expected mass for HIV-
1 NC p7 containing six pyridylethyl-cysteine residues is
6981.4 Da, and the observed mass was 6987.3 Da (0.08%
difference). While untreated NC had an A255/A280 ratio of 0.55
(see previous section), NC that was fully derivatized had an A255/
A280 ratio of 3.58, similar to the absorbance ratios of 3.4 and 3.51
observed above for the final NC reaction products from whole
virus treated with 4-VP and TPEN.
Discussion
Whole virus is efficiently inactivated by comparatively strong
oxidizing reagents such as AT-2 or alkylating agents such as
NEM, and it is presumed that the principal targets formodification
are the Cys residues of the NC protein (Morcock et al., 2005;
Rossio et al., 1998). However, there are a number of other proteins
in HIV-1 virions that contain Cys, so the argument for NC being
the principal target is based on indirect evidence. For instance, RT
contains several cysteine residues, but exogenous template RT
activity is essentially unaffected by AT-2, NEM, or, in the present
case, 4-VP+TPEN (Table 1; above references) so RT does not
appear to be a principal target. However, reverse transcription
processes during infection show profound defects with these
treatments (Morcock et al., 2005; Rossio et al., 1998; Table 1).
In addition, experiments that compared the sensitivity of two
divergent retroviruses, Moloney murine leukemia virus (MuLV)
and human foamy virus (HFV), to the sulfhydryl reagent AT-2
showed that the infectious titer of MuLV (an orthoretrovirus
containing NC zinc fingers) is reduced, but HFV (a spumare-
trovirus lacking zinc fingers) is unaffected by the reagent (Rein
et al., 1996). Taken together, these results suggest that the
cysteines in NC, a protein that is central to reverse transcription
processes through its chaperone function (Levin et al., 2005; Rein
et al., 1998), are the principal targets for these sulfhydryl reagents.
The present study investigates the impact of a mildly reactive
sulfhydryl reagent on HIV-1 infectivity, and thereby explores the
requirement for modifying NC rather than other non-Zn2+-
complexed Cys residues. Uniquely characteristic to this system,
used alone, 4-VP was poorly effective at inactivating HIV-1 and
alkylating NC unless a metal chelator was added. In infectivity
assays, 4-VP reduced viral titer by one order ofmagnitude after 24 h
of treatment (Fig. 1A). However, adding TPEN greatly increased
the rate and extent of virus inactivation, reducing infectivity by 4.5
orders of magnitude within 8 h (Fig. 1B). In addition, HPLC
analyses demonstrated that the NC protein was completely
modified by 4-VP+chelator treatment (Figs. 2D and 3B). Sig-
nificant differences in reverse transcription during infection were
also observed between the 4-VP treatments, with and without thechelator (Table 1). Singly, 4-VP reduced vDNA synthesis only two-
to three-fold while reducing integration 14-fold. In contrast, when
the reagent was combined with TPEN, synthesis of minus-strand
strong-stop DNA was reduced 15-fold, synthesis of plus-strand
transfer DNA was reduced 1200-fold, and proviruses were
undetectable (N1500-fold reduction based on detection limits;
Table 1). These results support the conclusion that NC cysteines are
sufficient targets for virus inactivation by sulfhydryl reagents.
The difference between these two treatments can be explained
by 4-VP's selective reactivity with NC, based upon Zn2+ coor-
dination in the zinc fingers. Chromatographic analysis showed
that, in contrast to the sulfhydryl reagent NEM (Chertova et al.,
1998; Morcock et al., 2005), 4-VP did not readily react with NC,
in purified form or within virions, while the protein's cysteine
residues were coordinated by Zn2+ (Figs. 2B and 3A). NC in
virions reacted rapidly and extensively only when HIV-1 was
treated with 4-VP in the presence of TPEN, but none of the other
major viral proteins detected in our HPLC assay showed
increased reactivity after the combined treatment (Figs. 2C and
D). AddingTPEN toHIV-1would have removed coordinatedZn2+
from the NC zinc finger domains, allowing 4-VP to react with the
newly exposed cysteines and unfold NC zinc fingers. Since NC
acts as a nucleic acid chaperone during reverse transcription (Levin
et al., 2005; Rein et al., 1998), unfolded zinc finger motifs could
account for the observed defect in vDNA synthesis and the loss of
infectivity seen after combination treatment.
The defect of reverse transcription, demonstrated by the sig-
nificant decrease in minus-strand strong-stop DNA, could be
caused by inhibition of primer annealing, defects in initiation, or
incomplete elongation of vDNA. A defect in annealing of the
tRNA primer can be discounted since (i) it would have certainly
taken place prior to 4-VP treatment, and (ii) does not require NC
zinc fingers (Hargittai et al., 2004) and would not be impaired
by their unfolding. On the other hand, NC zinc fingers are im-
portant for the initiation and elongation of minus-strand strong-
stop DNA synthesis (Huang et al., 1998b; Levin et al., 2005;
Rong et al., 1998, 2001). This could account for the defect
during initiation or elongation of minus-strand strong-stop DNA
synthesis in reverse transcription after 4-VP+TPEN treatment.
Of course, if reverse transcription does proceed, these defects
would become compounded over the subsequent steps in reverse
transcription and this is in fact observed in the more drastic
reduction in late vDNA products (Table 1).
However, our results cannot exclude the possibility that
proteins other than NC may have been modified by 4-VP.
Although it is unlikely that RT is affected (see above), integrase
(IN) has six cysteines distributed among its three structural
domains: two cysteines in the HHCC zinc finger domain, three in
the catalytic domain and one in the C-terminal domain (Engelman
et al., 1995). Data presented here showed that 4-VP did not react
with Zn2+-bound cysteines withinNC,which (provided this holds
true for other Zn2+-binding proteins) would preclude IN's HHCC
domain. In the case of the C-terminal cysteine, mutation of this
residue to a serine did not impair replication (Bischerour et al.,
2003). For the cysteines in the catalytic domain of IN, their
modification may be involved in the integration defect observed
(Table 1) and this also could account for the modest decrease in
154 D.R. Morcock et al. / Virology 375 (2008) 148–158viral titer with 4-VP (Fig. 1B). When the cysteines in the catalytic
domain are modified by NEM in vitro, IN binds poorly to vDNA
(Ellison et al., 1995), although it should be noted that mutation of
these cysteines does not affect in vitro enzymatic activity (Zhu
et al., 2004).
Genetic studies have shown that mutating cysteines within the
catalytic domain of IN can inhibit replication.When replacing the
three cysteines in the catalytic domain of IN with serines, only
mutation of the third cysteine (Cys130Ser) leads to noninfectious
virus (Zhu et al., 2004). However, the phenotype of HIV-1 with
Cys130Ser-IN differs from that observed with either the 4-VP or
4-VP+TPEN treatments. In particular, this mutation appears to
completely block vDNA synthesis as nominus-strand strong-stop
DNA could be detected, even 8 h after infection (Zhu et al., 2004).
In contrast, our experiments detected low levels of minus-strand
strong-stop at 24 h post-infection with either the 4-VP or 4-VP+
TPEN treatments (50%or 6%ofwild-type, respectively; Table 1).
Interestingly, treatment of HIV-1 with sulfhydryl reagents that are
more reactive than 4-VP [e.g. AT-2 (Rossio et al., 1998) or NEM
(Morcock et al., 2005)] virtually eliminated minus-strand strong-
stop DNA (b0.1% of wild-type), raising the possibility that, with
the AT-2 and NEM treatments, derivatized IN may be a factor in
defective vDNA synthesis. Another study showed that the
Cys130Gly-IN mutant is also noninfectious because of defective
vDNA synthesis (Lu et al., 2004a; Petit et al., 1999), but the
Cys130Ala-IN mutant replicates at nearly wild-type levels (Lu
et al., 2004a). Whether derivatization of IN cysteines would
interfere with reverse transcription in the context of chemically
inactivated HIV-1 is uncertain. Based on the results of 4-VP+
TPEN treatment, chemical modification may not be as detrimental
to reverse transcription as the above mentioned point mutations
are. Although INCys130 clearly influences vDNA synthesis, none
of the mutants produce a phenotype matching the inhibition of
vDNA integration observed with our 4-VP treatments.
It should also be mentioned that disruption of the zinc finger
domain of IN by mutagenesis results in viruses that show defects
in reverse transcription after infection. The synthesis of early as
well as late reverse transcripts were∼4% of wild-type virus, thus
once reverse transcription started in these mutants, it went to
completion (Masuda et al., 1995). This phenotype is in contrast to
the 4-VP+TPEN results that were obtained in this chemical
inactivation study where reverse transcription processivity (i.e.
synthesis of late vDNA products) was severely affected.
AT-2 reacts readily with Zn2+-bound cysteines, cross-linking
NC andother viral proteins via disulfide bond formation (Chertova
et al., 2003; Rossio et al., 1998). This reagent destroys the structure
of NC's zinc fingers, but it is not possible to separate the effects of
zinc finger unfolding from protein cross-linking. Using reagents
with a different chemistry, covalent addition to cysteine sulfurs,
allows better identification of a treatment's mechanism. Experi-
ments with such reagents, for example NEM (Morcock et al.,
2005), 3-nitrosobenzamide (Rice et al., 1993), and 4-VP+TPEN
(this study) show that cross-linking NC is not required for chem-
ical inactivation of HIV-1. However, because of their potency, all
three of these reagents can react with proteins other than NC.
Conclusively identifying the protein(s) responsible for inactivation
is therefore difficult. The results presented here showed that 4-VP,a milder reagent that is essentially unreactive with the Zn2+-bound
cysteines ofNC,was poorly effective unless combinedwith a Zn2+
chelator. This further supports the conclusion that Zn2+-bound
cysteines are critical targets for sulfhydryl reagents and empha-
sizes the important role of NC zinc fingers in virus inactivation.
Our study focused on viral proteins, but cellular proteins may
also be involved in this inactivation mechanism. Viral replication
depends on interactions with many host cell proteins (Dvorin and
Malim, 2003; Goff, 2007; Trkola, 2004), and HIV-1 virions
contain numerous cellular proteins (Chertova et al., 2006; Ott,
2002, in press). Some of these proteins can be expected to react
with sulfhydryl reagents, and their derivatization may affect rep-
lication by inhibiting enzymatic activities directly or by altering
protein interaction surfaces among cellular or viral proteins.
However, our HPLC analysis lacks sufficient sensitivity to in-
vestigate these less abundant proteins.
As a reagent used to derivatize cysteine for protein analysis,
4-VP is well characterized (Friedman, 2001; Friedman et al.,
1970). Use of 4-VP to treat whole virus has not been reported
previously, and this reagent's ability to react selectively with
cysteine thiols lacking coordinated Zn2+ may be useful for in-
vestigating the role of Zn2+ in protein function within intact
virions, generally. In contrast to point mutations, 4-VP treatment
allows the examination of virions that have assembled, budded and
matured normally, permitting another method for the characteriza-
tion of early infection events (Thomas and Gorelick, in press).
Materials and methods
Reagents
Chemicals were purchased from Sigma (St. Louis, MO)
unless stated otherwise. Stock solutions of 100 mM 4-VP were
made in 100 mM HCl; 400 mM GSH was dissolved in
Dulbecco's phosphate buffered saline without Ca2+ or Mg2+
(PBS; Invitrogen, Carlsbad, CA) supplemented with 400 mM
NaOH (to neutralize GSH acidity); TPEN was dissolved at
100 mM in absolute ethanol then diluted to 10 mM with PBS.
GSH and 4-VP stock solutions were made on the day of use.
Generation of virus stocks
HIV-1 was obtained by transfecting HEK 293T/ clone 17 cells
(American Type Culture Collection, Manassas, VA) in 75 cm2
culture flasks (Corning Life Sciences, Lowell, MA) with pNL4-3
(GenBank accession number: AF324493;Adachi et al., 1986) and
TransIT293 reagent (Mirus Bio Corporation, Madison, WI) ac-
cording to the manufacturer's instructions, and cultured over-
night. The cells were grown in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 2 mM L-glutamine or
2 mM L-alanyl-L-glutamine, 100 U of penicillin and 100 μg of
streptomycin per mL (Invitrogen), and 10% fetal bovine serum
(FBS; Cambrex, Walkersville, MD, or Invitrogen). The next day,
cells were rinsed twice with 5 mL of warmedmedium then 15mL
of fresh medium was added, and the cells were cultured for 24 h.
Culture fluid was clarified by centrifugation for 5 min at 1000 rpm
(284 ×g) using a JS-4.2 rotor (Beckman Instruments, Fullerton,
155D.R. Morcock et al. / Virology 375 (2008) 148–158CA) and again for 10min at 4000 rpm (3297 ×g). Virus stockswere
used fresh for experiments in Fig. 1. Alternatively, clarified
supernatant was layered over 10 mL of 20% (w/v) sucrose in PBS
and concentrated by ultracentrifugation at 27,000 rpm (131,453 ×g)
for 60 min in an SW28 rotor (Beckman Instruments). Pelleted
material was resuspended in 300 μL PBS and centrifuged at
60,000 rpm (156,845 ×g) for 20min in a TL-100.1 rotor (Beckman
Instruments). Supernatant was removed and the virus-containing
pellet was stored at −80 °C until HPLC analysis.
Infectivity assay
Viral infectivity was assayed with TZM-bl indicator cells,
HeLa cells engineered to express CD4, CXCR4, CCR5 and,
under control of HIV-1 LTR promoters, the β-galactosidase and
luciferase genes (Derdeyn et al., 2000; Platt et al., 1998;Wei et al.,
2002). Cells were grown in DMEM as described for the HEK
293T/ clone 17 cells above. TZM-bl cells were obtained through
the NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH from Dr. John C. Kappes, Dr.
Xiaoyun Wu and Tranzyme Inc. HIV-1 from fresh stocks (see
above) was mixed with various concentrations of 4-VP, with or
without 50 μM TPEN, and incubated at 37 °C. Samples were
collected over a 24 h period of incubation as indicated. GSH at
4mMwas added to quench any unreacted 4-VP, and 100 μMzinc
chloride or zinc acetate was added to samples containing TPEN to
prevent cellular toxicity. Parallel control incubations of virus
stocks with GSH, Zn2+, GSH+Zn2+ or ethanol at the levels used
with the 4-VP and TPEN experiments were also performed to
monitor the effects of these reagents on infectivity.
Infectivity assays were performed by seeding white, flat-
bottomed 96-well tissue culture-treated plates (Corning Life
Sciences) with 1×104 cells per well in 100 μL of medium as
indicated above. 24 h later, the virus samples, treated as indicated,
were diluted three-fold serially over 11 dilutions in medium con-
taining 2 μg/mL hexadimethrine bromide (polybrene; Sigma).
Then the medium was removed from the wells and replaced with
100 μL of each dilution, including an undiluted sample, and the
plates were incubated for 48 h at 37 °C in 5% CO2. The medium
was removed and wells were filled with 150 μL of ice-cold fixative
[PBS containing 2% (v/v) glutaraldehyde (Sigma) and 2% (v/v)
formaldehyde (Sigma)] and incubated for 5 min. The fixative was
removed and the wells filled with 150 μL of ice-cold PBS and
allowed to incubate for an additional 5min. The PBS rinsewas then
removed and replaced with 100 μL of developer [1.0 mg/mLX-gal
(5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside; Invitrogen),
7 mM potassium ferricyanide, 7 mM potassium ferrocyanide,
and 4 mMMgCl2 in PBS] and the plates were incubated for 3 h at
37 °C. The developer was removed, the plates rinsed 2× with
200 μL PBS (at room temperature) per well, blotted to remove
excess liquid, then 200 μL methanol per well was added and
immediately discarded and blotted. Plates were allowed to air dry
and blue cells in each well were counted using an automated
ELISPOT plate reader (Zellnet Consulting, New York, NY). Wells
containingmedium only were used to determine background levels
of blue cells, which were typically b1.6 blue cell forming units per
mL (BCFU/mL).Statistical analysis
Data from Fig. 1Bwas analyzed using single-factor analysis of
variance (ANOVA) followed by post hoc Tukey's test for
pairwise comparisons (Zar, 1999; Richardson and Overbaugh,
2005). These analyses were performed on the common (base 10)
logarithms of the normalized titer. The probability (p) values
obtained are those determined using the Tukey test; probability
values less than 0.05 were considered significant.
Reverse transcription
Infection of HOS cells with VSV-G pseudotyped HIV-1
stocks obtained by transfection were performed as described
previously (Julias et al., 2001). Briefly, HEK 293T cells were
cotransfected by calcium phosphate precipitation with the
proviral pNL4-3 Env− plasmid (Ott et al., 1999) and pHCMV-
g (Burns et al., 1993), which expresses the VSV-G protein. To
reduce contaminating plasmid DNA from the analysis of reverse
transcription products, transfected cultures were washed exten-
sively after transfection with PBS containing 1% calf serum as
described in Buckman et al. (2003). Two days after transfection,
pseudotyped virus was harvested from the culture medium,
clarified by low speed centrifugation, passed through a 0.22 μm
Millex-GS filter (Millipore, Billerica, MA) and polybrene was
added to a final concentration of 2 μg/mL. Virus was then treated
for 18 h at 37 °C as described in the Results section. Aliquots
were taken from each treatment for exogenous template RT
assays as described previously (Gorelick et al., 1990, 1999).
HOS cells were then infected with the treated viruses, and 24 h
post-infection, cells were harvested from plates and total cellular
DNA was extracted using the DNA Blood Mini Kit (Qiagen,
Valencia, CA). HOS cells were cultivated at 37 °C in 5% CO2
with the DMEM medium described above except that it
contained 5% FBS and 5% calf serum instead of 10% FBS.
Quantitative PCR employed an ABI Prism 7700 sequence
detection instrument (Applied Biosystems, Foster City, CA) using
the primers, probes, and PCR conditions described previously
(Buckman et al., 2003; Thomas et al., 2006). The vDNA copy
numbers were normalized for DNA recovery by measuring the
copy number of the cellularCCR5 gene (Thomas et al., 2006) and
for virus particles by exogenous template RT activity (see above).
The completion of early and late steps in reverse transcription was
determined by measuring copy numbers of minus-strand strong-
stop (R-U5) and plus-strand transfer (R-5′UTR) DNA targets,
respectively, after 24 h of infection of the HOS cells with VSV-G
pseudotyped HIV-1 as described (Buckman et al., 2003). The
formation of proviruses was measured with an Alu-LTR assay
described byButler et al. (2001), modified as described in Thomas
et al. (2006).
HPLC
Whole virus lysates and wild-type recombinant NC, prepared
as described in Carteau et al. (1999) or Wu et al. (1996) were
analyzed by microcapillary high-pressure liquid chromatography
(HPLC). Pelleted virus from HIV-1 pNL4-3 transfections
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[6.2 M guanidine–HCl (Pierce Biotechnology, Rockford, IL),
1 M NaCl and 2% (v/v) β-mercaptoethanol in 10 mM Tris
buffer, pH 8.5] and reduced for 1 h at room temperature; 10 μL
aliquots were stored at −80 °C until used. Reverse phase HPLC
was performed at a flow rate of 10 μL/min in a 500 μm×100 mm
column packed with 10 μm Poros R2/H poly(styrene-divinyl-
benzene) beads (Applied Biosystems) using a MicroPro pumping
system (Eldex Laboratories, Napa, CA) with an Agilent 1100
diode-array detector (Agilent Technologies, Santa Clara, CA).
Absorbance was recorded at 206, 255, and 280 nm. Column
temperature was maintained at 30 °C. Solvent Awas 0.1% (v/v)
trifluoroacetic acid and during whole viral lysate analysis, a
gradient of increasing solvent B (0.1% (v/v) trifluoroacetic acid
in 90% (v/v) acetonitrile) was added as follows: 5% B, 0–5 min;
5–12% B, 15 min; 12–37% B, 92 min; 37–50% B, 212 min;
50–66% B, 232 min; 66–100% B, 242 min; and 100% B,
253 min. For experiments with purified NC, the gradient of
increasing solvent B in Awas: 5–32% B, 60 min; 32% B, 5 min;
32–67%B, 5min; and 67%B, 5min. HPLC peaks corresponding
to HIV-1NL4-3 p1 (SP2) and p6 Gag proteins, which lack cysteine
(Henderson et al., 1988), were used as internal standards to
compensate for variation in the amount of protein and gradient
fluctuations caused by back-pressure variations between chro-
matographic runs. The data were normalized to equal time be-
tween p1 and p6 then aligned using a peak between these Gag
proteins, p6f (Henderson et al., 1988; N-terminal fragment of p6,
a.a. 1–36; analyzed with a Procise model 494 protein sequencer,
Applied Biosystems). Peak height was normalized to p6f, and
baseline was adjusted to a normalized scale. A255/A280 ratios were
calculated from peak height above baseline.
Mass spectrometry
HPLC fractions from purified NC experiments were analyzed
by matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry using a Kratos Kompact Probe MALDI
mass spectrometer (Kratos Analytical, Chestnut Ridge, NY) as
described previously (Morcock et al., 2005). Bovine insulin
(5734.6 Da) and ubiquitin (8565.9 Da) were used as molecular
mass standards.
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